Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.
2.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
3.
4.
6.

Risk-benefit assessment of angiotensin II receptor antagonists.

Shusterman N.

Expert Opin Drug Saf. 2002 Jul;1(2):137-52. Review.

PMID:
12904148
7.

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A.

Expert Opin Pharmacother. 2007 Apr;8(5):529-35. Review.

PMID:
17376010
8.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
9.

The preclinical basis of the therapeutic evaluation of losartan.

Timmermans PB, Wong PC, Chiu AT, Smith RD.

J Hypertens Suppl. 1995 Jul;13(1):S1-13. Review.

PMID:
18800450
10.

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.

Israili ZH.

J Hum Hypertens. 2000 Apr;14 Suppl 1:S73-86. Review.

PMID:
10854085
12.

First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.

Sawhney JP.

Indian Heart J. 2010 Jan-Feb;62(1):49-56. Review.

PMID:
21180035
13.

Update on role of direct renin inhibitor in diabetic kidney disease.

Dhakarwal P, Agrawal V, Kumar A, Goli KM, Agrawal V.

Ren Fail. 2014 Jul;36(6):963-9. doi: 10.3109/0886022X.2014.900425. Epub 2014 Mar 31. Review.

PMID:
24678880
14.
15.

[Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].

Abassi Z, Armaly Z, Nakhoul F, Hoffman A.

Harefuah. 2008 Jun;147(6):536-42, 573. Review. Hebrew.

PMID:
18693632
16.

An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.

Aulakh GK, Sodhi RK, Singh M.

Life Sci. 2007 Aug 2;81(8):615-39. Epub 2007 Jun 28. Review.

PMID:
17692338
17.

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Werner C, Pöss J, Böhm M.

Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Review.

PMID:
20568830
18.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
19.

Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.

Bomback AS, Toto R.

Am J Hypertens. 2009 Oct;22(10):1032-40. doi: 10.1038/ajh.2009.138. Epub 2009 Aug 6. Review.

PMID:
19661925
20.

Aliskiren and valsartan combination therapy for the management of hypertension.

Epstein BJ.

Vasc Health Risk Manag. 2010 Sep 7;6:711-22. Review.

Items per page

Supplemental Content

Write to the Help Desk